Table 2 Clinical characteristics of PC GC with and without gene rearrangements
From: FGFR2 alteration as a potential therapeutic target in poorly cohesive gastric carcinoma
|  | No. of patients | With rearrangements n = 9 (%) | Without rearrangements n = 19 (%) | Pa |
|---|---|---|---|---|
Age (years) | 0.371 | |||
 < 60 | 20 | 5 (55.6%) | 15 (78.9%) |  |
 ≥ 60 | 8 | 4 (44.4%) | 4 (21.1%) |  |
Gender | 0.249 | |||
Male | 17 | 7 (77.8%) | 10 (52.6%) | Â |
Female | 11 | 2 (22.2%) | 9 (47.4%) | Â |
AJCC | 0.010 | |||
 IIIA–B | 17 | 2 (22.2%) | 15 (78.9%) |  |
 IIIC | 11 | 7 (77.8%) | 4 (21.1%) |  |
T stage | 1.000 | |||
 3 | 17 | 5 (55.6%) | 12 (63.2%) |  |
 4a–4b | 11 | 4 (44.4%) | 7 (36.8%) |  |
N stage | 0.001 | |||
 1–3a | 19 | 2 (22.2%) | 17 (89.5%) |  |
 3b | 9 | 7 (77.8%) | 2 (10.5%) |  |
Tumor size (cm) | Â | |||
 ≤ 4 | 10 | 4 (44.4%) | 6 (31.6%) | 0.677 |
 > 4 | 18 | 5 (55.6%) | 13 (68.4%) |  |
Tumor location | 0.370 | |||
 Upper | 7 | 4 (44.4%) | 3 (15.8%) |  |
 Middle | 7 | 1 (11.1%) | 6 (31.6%) |  |
 Lower | 10 | 3 (33.3%) | 7 (36.8%) |  |
 Overlap | 4 | 1 (11.1%) | 3 (15.8%) |  |
PD-L1 | 0.689 | |||
 Negative | 15 | 4 (44.4%) | 11 (57.9%) |  |
 Positive | 13 | 5 (55.6%) | 8 (42.1%) |  |
PD-1 | 1.000 | |||
 Negative | 22 | 7 (77.8%) | 15 (78.9%) |  |
 Positive | 6 | 2 (22.2%) | 4 (21.1%) |  |
CD3 | 0.420 | |||
 Low | 14 | 3 (33.3%) | 11 (57.9%) |  |
 High | 14 | 6 (66.7%) | 8 (42.1%) |  |